Revance Therapeutics reported $640.88M in Assets for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Assets Change
Adamas Pharmaceuticals ADMS:US 150.64M 18.6M
Aerie Pharmaceuticals AERI:US $ 355.53M 7.2M
ALKERMES ALKS:US $ 1937.57M 59.35M
Antares Pharma ATRS:US $ 212.62M 5.84M
Biodelivery Sciences International BDSI:US $ 250.33M 8.2M
Bristol Myers Squibb BMY:US $ 110797M 1638M
Cara Therapeutics CARA:US $ 221.45M 28.77M
Coherus Biosciences CHRS:US $ 739.54M 46.24M
Eli Lilly And LLY:US $ 47809M 970.7M
Endo International Ordinary Shares ENDP:US $ 9206.26M 27.91M
Flexion Therapeutics FLXN:US $ 210.05M 20.33M
Gw Pharmaceuticals GWPH:US $ 934.34M 5.17M
Horizon Pharma HZNP:US $ 8207.42M 360.81M
JAZZ PHA JAZZ:US $ 13212.99M 6456.52M
Neurocrine Biosciences NBIX:US $ 1956.4M 110M
Pacira Pharmaceuticals PCRX:US $ 1325.83M 38.28M
Procter & Gamble PG:US $ 119307M 2529M
Revance Therapeutics RVNC:US $ 640.88M 35.07M
Supernus Pharmaceuticals SUPN:US $ 1573.06M 65.62M
Teva Pharmaceutical Industries TEVA:US $ 49195M 191M
Zogenix ZGNX:US $ 540.07M 40.89M